M C Fiore's research while affiliated with University of Wisconsin–Madison and other places

... Fiore M C et al [21] and Gill et al 22 , showed a 17% abstinence rate for non-alcoholic smokers receiving nicotine patch therapy, and 9.1% of participants in the six-month intensive treatment condition were proven to be abstinent which was similar to our study. ...

Reference:

The Effect of Behavioural Modification Therapy on Tobacco Cessation among Patients Visiting a Dental Institution in Bangalore – A Pragmatic Study

... Many quit attempts fail during the first week when withdrawal symptoms are strongest. 3,4 The few studies that have examined race/ ethnicity and withdrawal report some group differences. Among 1007 current smokers 5 , non-Hispanic White adults reported a greater number of withdrawal symptoms than non-Hispanic Black adults (M = 4.40, SD = 2.17 vs. M = 3.0, SD = 2.02; p = .001). ...

Reference:

Racial/Ethnic Differences in Self-reported Withdrawal Symptoms and Quitting Smoking Three Years Later: A Prospective, Longitudinal Examination of US Adults

... Before NRT was prescribed, we obtained approval from each woman's physician. The Agency for Health Care Policy and Research guidelines of 1996 had cautioned against use of NRT by patients within 6 weeks of an acute coronary event, 24 but thereafter the safety of NRT was confirmed, even for such cardiac patients, 20 on the basis of a favorable risk-to-benefit ratio associated with NRT usage as opposed to the patient's continued smoking. NRT became available on an over-the-counter basis after the present study began, but some participants in both groups obtained NRT and, very late in the study, bupropion (an antidepressant and a non-nicotine aid to smoking cessation) from their personal physicians. ...

Reference:

High Rates of Sustained Smoking Cessation in Women Hospitalized With Cardiovascular Disease The Women’s Initiative for Nonsmoking (WINS)

... Yet, the following aspects need to be considered in patients with CVDs. Nicotine replacement products (nicotine gum, inhaler, nasal spray, transdermal patch, sublingual tablet, or lozenge) reliably increases long-term smoking abstinence rates [2], but medical contraindications to nicotine replacement therapy include recent myocardial infarction or stroke [24,25]. The contraindication to nicotine replacement therapy soon after acute coronary syndrome remains unclear [26,27]. ...

Reference:

GOLD COPD DOCUMENT 2023: a brief update for practicing cardiologists

... Prior research has demonstrated a dose-response relationship between the intensity of certain clinical interventions for smoking (e.g., length of counseling sessions) and tobacco abstinence rates (Fiore et al, 2008). Identifying subgroups of participants who are more or less likely to smoke during a quit attempt from week to week enables prioritization of resources to those individuals who may need more support in order to stay quit. ...

Reference:

A Bayesian Nonparametric Approach for Clustering Functional Trajectories over Time

... Pharmacological smoking cessation therapies have been shown to double the chances of quitting successfully when administered in adjunction to brief physician counselling 7 . Unfortunately, a limited number of drugs are available for use in such therapies. ...

Reference:

Efficacy of bupropion and varenicline genetic markers in choosing pharmacological treatment for smoking cessation, and implications for combining drugs: A randomized controlled trial -GENTSMOKING

... The primary outcome will be Quality Adjusted Life Years (QALYs). Although utility scores (EQ-5D) (The Euroqol Group, 1990) will be measured at the beginning and end of the study period, previous studies have demonstrated that the cost effectiveness of smoking-cessation programs is very dependent on the quit rates at 12 months and subsequent relapse rates (Cromwell, Bartosch, Fiore, Baker, & Hasselblad, 1998;Hughes, Peters, & Naud, 2008;Shearer & Shanahan, 2006). As the long-term benefits from smoking cessation (e.g., avoided cases of lung cancer) may not be evident for many years, the analysis will use a Markov state transition model to track costs and QALYs for a hypothetical cohort model of participants moving between specified health states at the end of each cycle. ...

Reference:

Design and conduct of a pragmatic randomized controlled trial to enhance smoking-cessation outcomes with exercise: The Fit2Quit study

... Between September and November 2021, we recruited 24 adult smokers through their local independent pharmacy in rural Appalachia. Participants were primarily recruited through an ask-advise-connect model in which pharmacists asked potential participants if they were smoking, advised them to quit, and connected them to our study if they were interested [34]. Other recruitment methods included flyers on prescription bags and store signage. ...

Reference:

Testing the feasibility of the QuitAid smoking cessation intervention in a randomized factorial design in an independent, rural community pharmacy

... Once people start smoking, they usually have a hard time quitting (Jarvis 2004). This is due to the addictive chemical nicotine, a main ingredient in tobacco (Fiore et al. 1996;Rothemich et al. 2008). Nicotine dependence arises when you react to nicotine and cannot stop without using it. ...

Reference:

Smoker’s Characteristics, General Health and their Perception of Smoking in Social Environment: A Study of Smokers in Rajshahi City, Bangladesh

... To assess general and anxiety-specific symptoms of nicotine withdrawal syndrome and to verify protocol compliance, participants completed the WSWS (28 items) at the neuroimaging session [70]. Items are rated on a 5-point scale, with 0 indicating 'strongly disagree' and 4 indicating 'strongly agree'. ...

Reference:

Acute nicotine abstinence amplifies subjective withdrawal symptoms and threat-evoked fear and anxiety, but not extended amygdala reactivity